Moleculin Biotech (NASDAQ:MBRX) stock is on the move Friday after the clinical-stage pharmaceutical company provided an update to investors.
According to a press release from Moleculin, the company is preparing to attend the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting. This is set to take place from Nov. 1 through Nov. 4 in Dublin, Ireland.
The latest update on its attendance plans includes approval of its abstract for a poster presentation during the event. The company notes that this presentation will cover its Phase 1b/2 Study of liposomal annamycin in patients with previously treated soft-tissue sarcomas (STS) with pulmonary metastases.
Investors that want to know more about this study and what it means for the company will want to keep track of that poster presentation. The presentation is set for Nov. 2 with the presenter being Brian Andrew Van Tine, MD, PhD, Professor of Medicine at the Washington University School of Medicine.
How This Affects MBRX Stock
While shares of MBRX stock were initially up during pre-market trading this morning, they’ve given up those gains as of this writing. As a result, the company’s shares are now down 1.8% compared to its prior closing price.
Investors will also note that only about 8,000 shares have changed hands this morning. For the record, its daily average trading volume is about 157,000 shares.
There’s even more stock market news traders need to know about down below!
We’re offering up the latest stock market coverage traders need to know about on Friday! Among that is what has shares of AgriFORCE Growing Systems (NASDAQ:AGRI) stock rising, the biggest pre-market stock movers this morning and more. All of that news is ready to go at the links below!
More Stock Market News for Friday
- Why Is AgriFORCE Growing Systems (AGRI) Stock Up 74% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
- Stock Market Crash Alert: Larry Summers Gives 3 Options for Fed Rate Hikes
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
